In recent years, chimeric antigen receptor (CAR) T‐cell therapy targeting CD19 or CD22 antigen has been used as a potent approach to treat refractory/relapsed (r/r) B‐cell acute lymphoblastic leukemia (B‐ALL) and achieved remarkable efficacy. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.